These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32066715)

  • 61. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study.
    Soares B; Kanevsky G; Teng CT; Pérez-Esparza R; Bonetto GG; Lacerda ALT; Uribe ES; Cordoba R; Lupo C; Samora AM; Cabrera P
    Psychiatr Q; 2021 Dec; 92(4):1797-1815. PubMed ID: 34463905
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A New Prediction Model for Evaluating Treatment-Resistant Depression.
    Kautzky A; Baldinger-Melich P; Kranz GS; Vanicek T; Souery D; Montgomery S; Mendlewicz J; Zohar J; Serretti A; Lanzenberger R; Kasper S
    J Clin Psychiatry; 2017 Feb; 78(2):215-222. PubMed ID: 28068461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants.
    Park H; Park CM; Woo JM; Shin JY; Lee EK; Kwon SH
    J Med Econ; 2021; 24(1):589-597. PubMed ID: 33879031
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression.
    Pilon D; Szukis H; Singer D; Morrison L; Sheehan JJ; Lefebvre P
    Curr Med Res Opin; 2020 May; 36(5):865-874. PubMed ID: 31985319
    [No Abstract]   [Full Text] [Related]  

  • 67. Vitamin D and the risk of treatment-resistant and atypical depression: A Mendelian randomization study.
    Arathimos R; Ronaldson A; Howe LJ; Fabbri C; Hagenaars S; Hotopf M; Gaughran F; Lewis CM; Dregan A
    Transl Psychiatry; 2021 Nov; 11(1):561. PubMed ID: 34737282
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Healthcare resource utilization in patients with treatment-resistant depression-A Danish national registry study.
    Jensen KJ; Gronemann FH; Ankarfeldt MZ; Jimenez-Solem E; Alulis S; Riise J; Bødker N; Osler M; Petersen J
    PLoS One; 2022; 17(9):e0275299. PubMed ID: 36166443
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.
    Tammiste A; Jiang T; Fischer K; Mägi R; Krjutškov K; Pettai K; Esko T; Li Y; Tansey KE; Carroll LS; Uher R; McGuffin P; Võsa U; Tšernikova N; Saria A; Ng PC; Eller T; Vasar V; Nutt DJ; Maron E; Wang J; Metspalu A
    J Psychopharmacol; 2013 Oct; 27(10):915-20. PubMed ID: 23926243
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence.
    Di Vincenzo JD; Lipsitz O; Rodrigues NB; Lee Y; Gill H; Kratiuk K; Subramaniapillai M; Mansur R; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Nov; 143():209-214. PubMed ID: 34507101
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An integrated precision medicine approach in major depressive disorder: a study protocol to create a new algorithm for the prediction of treatment response.
    Baune BT; Minelli A; Carpiniello B; Contu M; Domínguez Barragán J; Donlo C; Ferensztajn-Rochowiak E; Glaser R; Kelch B; Kobelska P; Kolasa G; Kopeć D; Martínez de Lagrán Cabredo M; Martini P; Mayer MA; Menesello V; Paribello P; Perera Bel J; Perusi G; Pinna F; Pinna M; Pisanu C; Sierra C; Stonner I; Wahner VTH; Xicota L; Zang JCS; Gennarelli M; Manchia M; Squassina A; Potier MC; Rybakowski F; Sanz F; Dierssen M
    Front Psychiatry; 2023; 14():1279688. PubMed ID: 38348362
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IL6-174G > C genetic polymorphism influences antidepressant treatment outcome.
    Carvalho S; Santos M; Lima L; Mota-Pereira J; Pimentel P; Maia D; Correia D; Gomes S; Cruz A; Medeiros R
    Nord J Psychiatry; 2017 Feb; 71(2):158-162. PubMed ID: 27796193
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression.
    Lauden A; Geishin A; Merzon E; Korobeinikov A; Green I; Golan-Cohen A; Vinker S; Manor I; Weizman A; Magen E
    Brain Behav Immun Health; 2021 Oct; 16():100313. PubMed ID: 34589804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis.
    Perugi G; Pacchiarotti I; Mainardi C; Verdolini N; Menculini G; Barbuti M; Angst J; Azorin JM; Bowden CL; Mosolov S; Young AH; Vieta E;
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):825-834. PubMed ID: 31227264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immune Dysregulation in Treatment-Resistant Depression: Precision Approaches to Treatment Selection and Development of Novel Treatments.
    Chin Fatt CR; Mayes TL; Trivedi MH
    Psychiatr Clin North Am; 2023 Jun; 46(2):403-413. PubMed ID: 37149353
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.
    Eisendrath SJ; Gillung EP; Delucchi KL; Chartier M; Mathalon DH; Sullivan JC; Segal ZV; Feldman MD
    BMC Complement Altern Med; 2014 Mar; 14():95. PubMed ID: 24612825
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Putative role of glial cells in treatment resistance depression: An updated critical literation review and evaluation of single-nuclei transcriptomics data.
    Sanadgol N; Miraki Feriz A; Lisboa SF; Joca SRL
    Life Sci; 2023 Oct; 331():122025. PubMed ID: 37574044
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study.
    Nie Z; Vairavan S; Narayan VA; Ye J; Li QS
    PLoS One; 2018; 13(6):e0197268. PubMed ID: 29879133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.